Compare FBIZ & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBIZ | ZVRA |
|---|---|---|
| Founded | 1909 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 485.9M | 472.9M |
| IPO Year | 2012 | 2015 |
| Metric | FBIZ | ZVRA |
|---|---|---|
| Price | $52.25 | $8.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $65.00 | $21.71 |
| AVG Volume (30 Days) | 22.8K | ★ 550.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.52% | N/A |
| EPS Growth | 14.23 | ★ 34.27 |
| EPS | ★ 5.94 | 1.16 |
| Revenue | N/A | ★ $23,612,000.00 |
| Revenue This Year | $15.69 | $333.64 |
| Revenue Next Year | $8.47 | $44.19 |
| P/E Ratio | $9.11 | ★ $7.60 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $42.18 | $6.19 |
| 52 Week High | $60.54 | $13.16 |
| Indicator | FBIZ | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 32.73 | 53.84 |
| Support Level | $46.71 | $8.61 |
| Resistance Level | $53.63 | $9.03 |
| Average True Range (ATR) | 1.75 | 0.36 |
| MACD | -0.48 | 0.02 |
| Stochastic Oscillator | 12.23 | 69.51 |
First Business Financial Services Inc operates as a bank holding company. The Bank operates as a business bank, delivering a full line of commercial banking products including commercial loans and commercial real estate loans, to meet the specific needs of small and medium-sized businesses, business owners, executives, professionals, and high-net-worth individuals. The company's products and services include commercial lending, SBA lending and servicing, asset-based lending, equipment financing, factoring, trust, and investment services, treasury management services, and a broad range of deposit products. Geographically all the business activity functioned through the region of the United States.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.